Scoop: Lit­tle-known Or­biMed-backed biotech clos­es $160M round to start gene ther­a­py tri­al

Fron­tera Ther­a­peu­tics, a Chi­na and US biotech, has closed a $160 mil­lion Se­ries B and re­ceived reg­u­la­to­ry clear­ance to test its first gene ther­a­py state­side, End­points News has learned.

Led by the largest share­hold­er, Or­biMed, the biotech has se­cured $195 mil­lion to­tal since its Sep­tem­ber 2019 found­ing, ac­cord­ing to an email re­viewed by End­points. The lead AAV gene ther­a­py pro­gram is for an undis­closed rare eye dis­ease, ac­cord­ing to the source.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER